Allergy Therapeutics (LON:AGY) Announces Earnings Results

Key Points

• Allergy Therapeutics reported quarterly EPS of GBX (0.38) and a negative net margin of 72.91% despite a reported return on equity of 227.10%, indicating operating losses alongside anomalous ROE figures.
• The company recorded revenue of GBX 3,628 million and its shares were flat at GBX 10.30 (market cap £652.25 million), trading 71,346 shares versus an average volume of 280,355 and a negative P/E of -12.26.
• Allergy Therapeutics is an international biotech focused on allergy immunotherapy vaccines, with a pipeline that includes grass, tree and house dust mite vaccines and a peanut vaccine in pre‑clinical development.

Allergy Therapeutics (LON:AGY - Get Free Report) posted its earnings results on Tuesday. The company reported GBX (0.38) EPS for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a positive return on equity of 227.10% and a negative net margin of 72.91%.The business had revenue of GBX 3,628 million for the quarter.

Allergy Therapeutics Price Performance

AGY remained flat at GBX 10.30 on Thursday. The company had a trading volume of 71,346 shares, compared to its average volume of 280,355. The company has a market capitalization of £652.25 million, a PE ratio of -12.26, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of -213.13, a quick ratio of 1.48 and a current ratio of 1.28. The stock's fifty day simple moving average is GBX 10.96 and its two-hundred day simple moving average is GBX 10.04. Allergy Therapeutics has a 12-month low of GBX 5 and a 12-month high of GBX 12.10.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.